WallStSmart

Novo Nordisk A/S (NVO)vsTC Energy Corp (TRP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 2018% more annual revenue ($327.80B vs $15.48B). NVO leads profitability with a 37.2% profit margin vs 22.2%. TRP appears more attractively valued with a PEG of 3.37. NVO earns a higher WallStSmart Score of 74/100 (B).

NVO

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.13

TRP

Buy

55

out of 100

Grade: C

Growth: 4.7Profit: 7.5Value: 3.3Quality: 3.0
Piotroski: 4/9Altman Z: 0.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for NVO.

TRPSignificantly Overvalued (-33.9%)

Margin of Safety

-33.9%

Fair Value

$45.51

Current Price

$64.75

$19.24 premium

UndervaluedFair: $45.51Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVO6 strengths · Avg: 10.0/10
Market CapQuality
$202.85B10/10

Mega-cap, among the largest globally

P/E RatioValuation
10.6x10/10

Attractively priced relative to earnings

Return on EquityProfitability
71.4%10/10

Every $100 of equity generates 71 in profit

Profit MarginProfitability
37.2%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
61.6%10/10

Strong operational efficiency at 61.6%

EPS GrowthGrowth
67.1%10/10

Earnings expanding 67.1% YoY

TRP4 strengths · Avg: 9.0/10
Operating MarginProfitability
47.5%10/10

Strong operational efficiency at 47.5%

Market CapQuality
$67.82B9/10

Large-cap with strong market position

Profit MarginProfitability
22.2%9/10

Keeps 22 of every $100 in revenue as profit

Free Cash FlowQuality
$1.10B8/10

Generating 1.1B in free cash flow

Areas to Watch

NVO2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

TRP4 concerns · Avg: 2.5/10
P/E RatioValuation
26.1x4/10

Moderate valuation

PEG RatioValuation
3.372/10

Expensive relative to growth rate

EPS GrowthGrowth
-8.5%2/10

Earnings declined 8.5%

Altman Z-ScoreHealth
0.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : NVO

The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.

Bull Case : TRP

The strongest argument for TRP centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 22.2% and operating margin at 47.5%.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio.

Bear Case : TRP

The primary concerns for TRP are P/E Ratio, PEG Ratio, EPS Growth. Debt-to-equity of 2.23 is elevated, increasing financial risk.

Key Dynamics to Monitor

NVO profiles as a growth stock while TRP is a mature play — different risk/reward profiles.

TRP carries more volatility with a beta of 0.97 — expect wider price swings.

NVO is growing revenue faster at 24.0% — sustainability is the question.

NVO generates stronger free cash flow (12.0B), providing more financial flexibility.

Bottom Line

NVO scores higher overall (74/100 vs 55/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

TC Energy Corp

ENERGY · OIL & GAS MIDSTREAM · USA

TC Energy Corporation is an energy infrastructure company in North America. The company is headquartered in Calgary, Canada.

Want to dig deeper into these stocks?